2.71

3.56% -0.10

After Hours: 2.76 0.05 +1.85%

Adverum Biotechnologies Inc (ADVM)

Overview News Price History Option Chain Financials Discussions Forecast

Adverum Biotechnologies Inc stock is traded at $2.71, with a volume of 621.15K. It is down -3.56% in the last 24 hours and down -20.99% over the past month. Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.

Previous Close:

$2.81

Open:

$2.97

24h Volume:

621.15K

Relative Volume:

2.17

Market Cap:

$75.00M

Revenue:

Net Income/Loss:

$-94.11M

P/E Ratio:

-0.4509

EPS:

-6.01

Net Cash Flow:

$-86.06M

1W Performance:

-24.51%

1M Performance:

-20.99%

6M Performance:

-65.65%

1Y Performance:

-70.86%

1-Day Range:

$2.66

$3.005

1-Week Range:

$2.66

$3.575

52-Week Range:

$2.64

$10.14

Adverum Biotechnologies Inc Stock (ADVM) Company Profile

Name

Adverum Biotechnologies Inc

Sector

Healthcare (1154)

Industry

Biotechnology (676)

Phone

(650) 649-1004

Address

100 CARDINAL WAY, REDWOOD CITY, CA

Employee

155

Twitter

@adverumbio

Next Earnings Date

2024-11-07

Latest SEC Filings

ADVM's Discussions on Twitter

Compare ADVM with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ADVM Adverum Biotechnologies Inc	2.71	75.00M	0	-94.11M	-86.06M	-6.01
VRTX Vertex Pharmaceuticals Inc	439.37	128.45B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	575.63	65.17B	14.09B	4.50B	2.96B	39.28
ARGX Argen X Se Adr	560.90	40.09B	2.58B	1.06B	-1.28B	16.33
ALNY Alnylam Pharmaceuticals Inc	270.19	35.67B	2.35B	-269.70M	-75.39M	-2.09
ONC Beigene Ltd Adr	233.25	27.44B	3.81B	-644.79M	-669.77M	-6.24

Adverum Biotechnologies Inc Stock (ADVM) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-25-24	Initiated	Oppenheimer	Outperform
Apr-30-24	Initiated	H.C. Wainwright	Buy
Jul-07-22	Upgrade	Truist	Hold → Buy
Jul-23-21	Downgrade	Cantor Fitzgerald	Overweight → Neutral
May-03-21	Downgrade	SVB Leerink	Outperform → Mkt Perform
Apr-29-21	Downgrade	Chardan Capital Markets	Buy → Neutral
Apr-29-21	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Apr-29-21	Downgrade	Truist	Buy → Hold
Dec-16-20	Initiated	UBS	Neutral
Nov-12-20	Upgrade	Raymond James	Underperform → Mkt Perform
Jun-26-20	Downgrade	Raymond James	Mkt Perform → Underperform
May-13-20	Initiated	RBC Capital Mkts	Outperform
May-05-20	Upgrade	SunTrust	Hold → Buy
Apr-28-20	Initiated	Goldman	Buy
Mar-16-20	Initiated	SVB Leerink	Outperform
Feb-10-20	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Feb-10-20	Upgrade	Chardan Capital Markets	Neutral → Buy
Oct-15-19	Reiterated	Chardan Capital Markets	Neutral
Sep-13-19	Reiterated	Chardan Capital Markets	Neutral
Jun-14-19	Resumed	Raymond James	Mkt Perform
Nov-02-18	Downgrade	Raymond James	Outperform → Mkt Perform
Nov-02-18	Downgrade	SunTrust	Buy → Hold
Sep-21-18	Initiated	Cantor Fitzgerald	Overweight
Aug-30-18	Initiated	SunTrust	Buy
Feb-15-18	Resumed	Piper Jaffray	Overweight
Oct-12-17	Initiated	Raymond James	Outperform

View All

Adverum Biotechnologies Inc Stock (ADVM) Latest News

May 07, 2025